The goal of this project is to better characterize the role of tumor necrosis factor (TNF) in the pathogenesis and treatment of asthma. TNF is capable of up-regulating a variety of important pro-inflammatory gene products that may contribute to asthmatic airway inflammation. Although anti-TNF approaches have been effective in animal models of asthma, the efficacy of an anti-TNF strategy in humans has not been studied. We have initiated a Phase II clinical trial utilizing a soluble, dimeric fusion protein comprised of the extracellular ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1 (TNFR:Fc). TNFR:Fc functions by binding TNF and blocking its interaction with cell surface receptors. This randomized, double-blinded, placebo-controlled, proof of concept trial will utilize a bronchoscopic segmental allergen challenge model in mild atopic asthmatics not requiring corticosteroid therapy. Four doses of TNFR:Fc will be administered via subcutaneous injection over a two-week period. Soluble and cellular inflammatory markers, as well as physiological parameters will be assessed pre- and post-TNFR:Fc therapy and following bronchoscopic segmental allergen challenge. The data generated by this study will assess the utility of future trials of anti-TNF therapy in asthma. Laboratory investigations are also being conducted to identify the mechanism via which ectodomain shedding of cell surface TNF receptors is regulated. For example, shedding of TNF receptors may have an anti-inflammatory effect via the generation of soluble TNF binding proteins and by decreasing the number of cell surface TNF receptors available for ligand binding. We hypothesized that the mechanism of TNFR1 shedding might involve interactions with regulatory ectoproteins. Utilizing a yeast two-hybrid approach, we identified ARTS-1 (Aminopeptidase Regulator of TNFR1 Shedding) as a type II integral membrane protein that binds to the TNFR1 extracellular domain. In vivo binding of membrane-associated ARTS-1 to TNFR1 was confirmed by co-immunoprecipitation experiments utilizing human pulmonary epithelial and umbilical vein endothelial cells. A direct relationship exists between membrane-associated ARTS-1 protein levels and concordant changes in TNFR1 shedding. Cells over-expressing ARTS-1 demonstrated increased TNFR1 shedding and decreased membrane-associated TNFR1, while cells expressing anti-sense ARTS-1 mRNA demonstrated decreased membrane-associated ARTS-1, decreased TNFR1 shedding and increased membrane-associated TNFR1. ARTS-1 neither bound to TNFR2 nor altered its shedding, suggesting specificity for TNFR1. Although a GST-ARTS-1 fusion protein demonstrated selective aminopeptidase activity towards non-polar amino acids, multiple lines of negative evidence suggest that ARTS-1 does not possess TNFR1 sheddase activity. These findings indicate that ARTS-1 is a multi-functional ectoprotein capable of binding to and promoting TNFR1 shedding. Therefore, we have proposed that formation of a TNFR1-ARTS-1 molecular complex represents a novel mechanism by which TNFR1 shedding is regulated. Ongoing investigations are assessing the mechanism by which ARTS-1 regulates TNFR1 shedding.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Intramural Research (Z01)
Project #
1Z01HL002544-04
Application #
6690542
Study Section
(PCCM)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
U.S. National Heart Lung and Blood Inst
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Adamik, Barbara; Islam, Aminul; Rouhani, Farshid N et al. (2008) An association between RBMX, a heterogeneous nuclear ribonucleoprotein, and ARTS-1 regulates extracellular TNFR1 release. Biochem Biophys Res Commun 371:505-9
Islam, Aminul; Shen, Xiaoyan; Hiroi, Toyoko et al. (2007) The brefeldin A-inhibited guanine nucleotide-exchange protein, BIG2, regulates the constitutive release of TNFR1 exosome-like vesicles. J Biol Chem 282:9591-9
Islam, Aminul; Adamik, Barbara; Hawari, Feras I et al. (2006) Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex. J Biol Chem 281:6860-73
Rouhani, Farshid N; Meitin, Catherine A; Kaler, Maryann et al. (2005) Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 99:1175-82
Levine, Stewart J; Adamik, Barbara; Hawari, Feras I et al. (2005) Proteasome inhibition induces TNFR1 shedding from human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 289:L233-43
Buckley, Caitriona A; Rouhani, Farshid N; Kaler, Maryann et al. (2005) Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch. Am J Physiol Lung Cell Mol Physiol 288:L1132-8
Levine, Stewart J (2004) Mechanisms of soluble cytokine receptor generation. J Immunol 173:5343-8
Hawari, Feras I; Rouhani, Farshid N; Cui, Xinle et al. (2004) Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci U S A 101:1297-302
Cui, Xinle; Rouhani, Farshid N; Hawari, Feras et al. (2003) An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem 278:28677-85
Cui, Xinle; Rouhani, Farshid N; Hawari, Feras et al. (2003) Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 171:6814-9

Showing the most recent 10 out of 11 publications